Cost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in women with early-stage estrogen- or progesterone-receptor-positive, axillary lymph-node negative breast cancer.

Cost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in women with early-stage estrogen- or progesterone-receptor-positive, axillary lymph-node negative breast cancer.

Item
http://www.wikidata.org/entity/Q34431985
Towards decision-making using individualized risk estimates for personalized medicine: A systematic review of genomic classifiers of solid tumors.Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013Cost-utility analyses of drug therapies in breast cancer: a systematic review.Health technology assessment and personalized medicine: are economic evaluation guidelines sufficient to support decision making?The Clinical Significance of Occult Gastrointestinal Primary Tumours in Metastatic Cancer: A Population Retrospective Cohort Study.Cost effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in post-menopausal women with early-stage estrogen or progesterone-receptor-positive, axillary lymph-node positive breast cancer.Cost-effectiveness of using a gene expression profiling test to aid in identifying the primary tumour in patients with cancer of unknown primary.Differential patterns of recurrence and specific survival between luminal A and luminal B breast cancer according to recent changes in the 2013 St Gallen immunohistochemical classification.The clinical significance of occult gynecologic primary tumours in metastatic cancer.Cost-Effectiveness Analyses of the 21-Gene Assay in Breast Cancer: Systematic Review and Critical Appraisal.Prolaris Cell Cycle Progression Test for Localized Prostate Cancer: A Health Technology Assessment
P2860

Cost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in women with early-stage estrogen- or progesterone-receptor-positive, axillary lymph-node negative breast cancer.

Item
http://www.wikidata.org/entity/Q34431985
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Cost-effectiveness of a 21-gen ...... h-node negative breast cancer.
@ast
Cost-effectiveness of a 21-gen ...... h-node negative breast cancer.
@en
Cost-effectiveness of a 21-gen ...... h-node negative breast cancer.
@nl
type
label
Cost-effectiveness of a 21-gen ...... h-node negative breast cancer.
@ast
Cost-effectiveness of a 21-gen ...... h-node negative breast cancer.
@en
Cost-effectiveness of a 21-gen ...... h-node negative breast cancer.
@nl
prefLabel
Cost-effectiveness of a 21-gen ...... h-node negative breast cancer.
@ast
Cost-effectiveness of a 21-gen ...... h-node negative breast cancer.
@en
Cost-effectiveness of a 21-gen ...... h-node negative breast cancer.
@nl
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P407
P478
P577
P5875
P6179
P698
P921
P932
P356
P1433
P1476
Cost-effectiveness of a 21-gen ...... h-node negative breast cancer.
@en
P2093
P2860
P2888
P304
P31
P356
P407
P478
P577
P5875
P6179
P698
P921
P932